Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Excellence Forum

Gastrointestinal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Anant Ramaswamy, MD, Tata Memorial Hospital
Videos
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
01/20/2024
A. Ramaswamy
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses...
01/20/2024
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer
11/16/2023
Sara Lonardi
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Berend van der Wilk, MD, Erasmus University Medical Center
Videos
Active Surveillance After Neoadjuvant Chemoradiation for Select Patients With Esophageal Cancer
11/07/2023
Berend van der Wilk, MD
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares...
11/07/2023
Oncology
Nataliya Uboha, MD, Carbone Cancer Center
Videos
Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers
09/29/2023
Nataliya Uboha, MD, PhD
At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Nataliya Uboha, MD, PhD, discusses the use of biomakers to choose the best treatment for patients with upper GI cancers.
At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Nataliya Uboha, MD, PhD, discusses the use of biomakers to choose the best treatment for patients with upper GI cancers.
At the Great Debates & Updates...
09/29/2023
Oncology
Matti Aapro, MD, Genolier Cancer Center
Videos
Anti-Emesis For Patients With Gastrointestinal Cancers
08/24/2023
Matti Aapro, MD
At the 2023 World Congress on Gastrointesinal Cancers, Matti Aapro, MD, discusses how to best address emesis among patients with gastrointestinal cancers.
At the 2023 World Congress on Gastrointesinal Cancers, Matti Aapro, MD, discusses how to best address emesis among patients with gastrointestinal cancers.
At the 2023 World Congress on...
08/24/2023
Oncology
Anna Wagner, MD, University of Lausanne
Videos
Addition of Trastuzumab to Perioperative Chemotherapy Improved Response Rates Among Patients with HER2-Positive Gastric or Gastroesophageal Junction Cancer
08/11/2023
Anna Dorothea Wagner, PD
At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.
At the 2023 World Congress on...
08/11/2023
Oncology
John Strickler, MD, Duke Cancer Center
Videos
Targeting KRAS in Gastrointestinal Cancers
07/14/2023
At the 2023 World Congress on Gastrointestinal Cancers, John Strickler, MD, reviews the currently available and upcoming strategies in targeting KRAS in gastrointestinal cancers.
At the 2023 World Congress on Gastrointestinal Cancers, John Strickler, MD, reviews the currently available and upcoming strategies in targeting KRAS in gastrointestinal cancers.
At the 2023 World Congress on...
07/14/2023
Oncology
Van Morris, MD, MD Anderson Cancer Center
Videos
Ipilimumab Added to Nivolumab Does Not Significantly Improve Survival Outcomes for Patients With Squamous Cell Carcinoma of the Anal Canal
07/13/2023
Van Morris, MD
At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...
At the 2023 World Congress on Gastrointestinal Cancers, Van Morris, MD, presented results from a phase 2 study evaluating the addition of ipilimumab to nivolumab for patients with previously treated, unresectable or metastatic squamous cell...
At the 2023 World Congress on...
07/13/2023
Oncology
Lucjan Wyrwicz, MD, Maria Sklodowska Curie National Cancer Research Institute
Videos
Continued Benefit From Pembrolizumab Plus Chemotherapy in Later-Line Therapy for Patients With Advanced, HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma
07/12/2023
L. Wyrwicz
At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...
At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...
At the 2023 World Congress on...
07/12/2023
Oncology
Anup Kasi, MD, University of Kansas Cancer Center
Videos
Adjuvant Immunotherapy for Upper GI Tract Cancers
04/20/2023
Anup Kasi, MD, discusses the debate on neoadjuvant vs adjuvant immunotherapy for patients with locally advanced HER2-positive upper gastrointestinal tract cancers, held at the 2023 Great Debates and Updates in GI Malignancies in Chicago.
Anup Kasi, MD, discusses the debate on neoadjuvant vs adjuvant immunotherapy for patients with locally advanced HER2-positive upper gastrointestinal tract cancers, held at the 2023 Great Debates and Updates in GI Malignancies in Chicago.
Anup Kasi, MD, discusses the...
04/20/2023
Oncology

Section Editor

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center, New York

Resources

Thierry Andre, MD, St Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer
02/04/2025
Thierry André, MD
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.
Thierry Andre, MD, describes...
02/04/2025
Oncology
Scott Kopetz, MD
Videos
Impact of Encorafenib Approval for BRAF V600E Mutant Colorectal Cancer
01/30/2025
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER trial which led to the recent FDA approval of encorafenib with cetuximab and mFOLFOX6.
Scott Kopetz, MD, PhD, discusses...
01/30/2025
Oncology
Xuefeng Leng, MD, PhD, Sichuan Cancer Hospital & Institute
Videos
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma
01/28/2025
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
Xuefeng Leng, MD, explains...
01/28/2025
Oncology
Anna Martling, MD, Karolinska Institutet
Videos
Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute
Videos
Treatment Patterns for Hepatocellular Carcinoma
12/18/2024
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.
Christopher Manz, MD, MSHP,...
12/18/2024
Oncology
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
Filippo Pietrantonio, MD
Videos
Amivantamab Plus Chemotherapy Demonstrates Antitumor Activity in Metastatic Colorectal Cancer
09/14/2024
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD,...
09/14/2024
Oncology
Jennifer Eads, MD, Abramson Cancer Center
Videos
Perioperative Chemotherapy Improved Survival Among Patients With Esophageal Adenocarcinoma
06/20/2024
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on the results from the ESOPEC trial, which found perioperative chemotherapy improved survival for patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation.
Jennifer Eads, MD, comments on...
06/20/2024
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Riccardo Lencioni, MD
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
Blog
Article: Selecting Second-Line Therapy for Relapsing/Remitting Pediatric Low-Grade Glioma (pLGG)
04/24/2025
Molecular profiling is revolutionizing pediatric low-grade glioma (pLGG) management, driving precision-targeted therapies and reshaping diagnostic, treatment, and monitoring paradigms.
Molecular profiling is revolutionizing pediatric low-grade glioma (pLGG) management, driving precision-targeted therapies and reshaping diagnostic, treatment, and monitoring paradigms.
Molecular profiling is...
04/24/2025
Oncology
Blog
Article: Targeted Therapies for Relapsing/Remitting Pediatric Low-Grade Glioma (R/R pLGG)
04/24/2025
With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With FDA-approved BRAF, MEK, and pan-RAF inhibitors transforming pediatric low-grade glioma (pLGG) care, learn how molecular targeting of MAPK pathway alterations is redefining frontline treatment strategies and outcomes.
With FDA-approved BRAF, MEK, and...
04/24/2025
Oncology
Round 3: For TTFields vs Against TTFields
04/24/2025
04/24/2025
Oncology
Round 2: Adding Radiation Therapy vs Switching Treatments
04/24/2025
04/24/2025
Oncology
Round 1: Immunotherapy vs Alternative Therapy
04/24/2025
04/24/2025
Oncology
Blog
Article: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)
04/24/2025
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
With nearly all pediatric low-grade glioma (pLGG) tumors driven by MAPK pathway activation, targeted therapies are redefining treatment by tailoring approaches to the tumor’s specific genetic signature.
With nearly all pediatric...
04/24/2025
Oncology
Navigating Post-Platinum Treatment Pathways for Metastatic NSCLC
04/24/2025
This thought-provoking debate features leading experts in thoracic oncology as they critically examine emerging strategies and ongoing challenges in the management of metastatic non–small cell lung cancer (NSCLC).
This thought-provoking debate features leading experts in thoracic oncology as they critically examine emerging strategies and ongoing challenges in the management of metastatic non–small cell lung cancer (NSCLC).
This thought-provoking debate...
04/24/2025
Oncology
FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use